Vivos Inc. Overview
Pro stress-test →Vivos Inc. (OTCQB: RDGL) has developed an Yttrium-90 based injectable brachytherapy device for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Using proprietary hydrogel technology, brachytherapy delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of external-beam radiation therapy.
Strategic Profile
Pro stress-test →The company received its Washington State Radioactive Materials License for IsoPet manufacturing in June 2026, enabling compliant in-house production at its Richland facility. In February 2025, the first five human patients demonstrated the safety of RadioGel Precision Radionuclide Therapy, with confirmation via PET imaging that the Y-90 remained at the point of injection and no adverse events reported.
Competitive Landscape
Pro stress-test →Vivos competes in radiation oncology as a brachytherapy device company focused on non-resectable tumors. Direct competitors include traditional external-beam radiation therapy providers and other emerging brachytherapy platforms. The dual-indication strategy (animal health via IsoPet and human oncology via RadioGel) differentiates the company but limits head-to-head competition in any single market segment.
Industry Context
Vivos Inc. operates in Brachytherapy medical devices.
Key facts
Founded: 1994 · Headquarters: Richland, Washington · Employees: Unknown · Revenue: Pre-revenue/Early-stage · Market cap: $32.7M